Coupang

Coupang shares fell to a 52-week low of $14.92 and are down 53.54% year-to-date, with a market capitalization of $27 billion. Despite annual revenue of $35.5 billion, the company remains unprofitable; adjusted earnings per share for Q2 were −$0.09, better than expected, while revenue of $8.9 billion missed analysts’ estimate of $9.07 billion. The EBITDA margin contracted by 320 basis points, Product Commerce grew 8% on a constant-currency basis, and BofA cut its price target to $24 but kept the rating at "Buy." Management expects Product Commerce margins to recover by mid-2027; data from InvestingPro indicate the stock is trading near its fair value. » More on de.investing.com

Coupang reported a Q2 GAAP operating loss driven by a $410 million Korean regulatory fine and a $548 million FX headwind, cutting reported revenue growth and collapsing free cash flow. Barclays maintains a $30 target, arguing the fine is one-time and highlighting 10% constant-currency growth, Developing Offerings expansion, logistics moat, and aggressive buybacks as recovery catalysts. The stock trades about 47% below the average analyst target and far worse than peers, but risks include further regulatory action, widening losses in Developing Offerings, and weakened balance sheet metrics. » More on finance.yahoo.com

Coupang reported an adjusted loss of $0.09 per share in Q2 2026, beating the consensus expectation of -$0.21. Revenue was $8.9 billion, about $170 million below estimates, after which the stock fell roughly 7% in after-hours trading. Product Commerce saw currency‑adjusted growth of 8% and 24.7 million active customers, while margins remained pressured by exchange rates, higher spending and regulatory fines. Management expects currency‑adjusted revenue growth of 8–9% for Q3 and margin compression in the Product Commerce segment, with margins projected to recover by mid‑2027. » More on de.investing.com